{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:16:50Z","timestamp":1789161410936,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004229","name":"Fondazione Pierfranco e Luisa Mariani","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004229","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.coi.2026.102725","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T17:36:47Z","timestamp":1769103407000},"page":"102725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A comprehensive study on the effect of alglucosidase alpha and immunomodulation on survival, motor and cardiac outcome, creatine kinase and antibody titers in classic infantile Pompe disease: the Monza experience"],"prefix":"10.1016","volume":"99","author":[{"given":"Martha C","family":"Faraguna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Crescitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Bonanomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia A","family":"Kullmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L","family":"Boffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Pretese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Risca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia M","family":"Tedesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Serafini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna MP","family":"van den Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ans T","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana C","family":"Balduzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8743-4407","authenticated-orcid":false,"given":"Serena","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2026.102725_bib1","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2026.102725_sbref2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s13023-024-03373-w","article-title":"The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II).","volume":"19","author":"Parenti","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.coi.2026.102725_bib3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"Van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.coi.2026.102725_bib4","article-title":"Characterization of immune response in cross-reactive immunological material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy","volume":"20","author":"Desai","year":"2019","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.coi.2026.102725_bib5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10545-014-9707-6","article-title":"Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease","volume":"38","author":"van Gelder","year":"2015","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.coi.2026.102725_bib6","first-page":"113","article-title":"Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk","author":"Van den Hout","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.coi.2026.102725_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid \u03b1-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.coi.2026.102725_bib8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.21037\/atm.2019.04.70","article-title":"Long-term outcome and unmet needs in infantile-onset Pompe disease","volume":"7","author":"Hahn","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.coi.2026.102725_sbref9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3233\/JND-230164","article-title":"Long-term outcome of infantile onset Pompe disease patients treated with enzyme replacement therapy - data from a German-Austrian Cohort","volume":"11","author":"Pfrimmer","year":"2024","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.coi.2026.102725_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-018-0771-0","article-title":"Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy","volume":"13","author":"Parini","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.coi.2026.102725_bib11","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/ene.15894","article-title":"Long-term follow-up of 64 children with classical infantile-onset Pompe disease since 2004: a French real-life observational study","volume":"30","author":"Tardieu","year":"2023","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.coi.2026.102725_bib12","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet Med"},{"key":"10.1016\/j.coi.2026.102725_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10545-015-9898-5","article-title":"Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy","volume":"39","author":"Broomfield","year":"2016","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.coi.2026.102725_bib14","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/jimd.12268","article-title":"Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients","volume":"43","author":"Poelman","year":"2020","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.coi.2026.102725_bib15","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10545-015-9912-y","article-title":"Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study","volume":"39","author":"van Gelder","year":"2016","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.coi.2026.102725_bib16","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1515\/jpem-2018-0336","article-title":"Early higher dosage of alglucosidase alpha in classic Pompe disease","volume":"31","author":"Spada","year":"2018","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.coi.2026.102725_sbref17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S2352-4642(21)00308-4","article-title":"Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium","volume":"6","author":"Ditters","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.coi.2026.102725_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-023-02981-2","article-title":"Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry","volume":"18","author":"Kishnani","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.coi.2026.102725_bib19","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jpeds.2017.11.046","article-title":"High sustained antibody titers in patients with classic infantile Pompe disease following immunomodulation at start of enzyme replacement therapy","volume":"195","author":"Poelman","year":"2018","journal-title":"J Pediatr"},{"key":"10.1016\/j.coi.2026.102725_sbref20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1360369","article-title":"An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation","volume":"15","author":"Desai","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102725_bib21","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.coi.2026.102725_bib22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.21037\/atm.2019.05.27","article-title":"Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review","volume":"7","author":"Desai","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.coi.2026.102725_bib23","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/eci.12.40","article-title":"Immune modulation in Pompe disease treated with enzyme replacement therapy","volume":"8","author":"Banugaria","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.coi.2026.102725_bib24","doi-asserted-by":"crossref","first-page":"1336599","DOI":"10.3389\/fimmu.2024.1336599","article-title":"Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102725_bib25","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","article-title":"High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa","volume":"101","author":"de Vries","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.coi.2026.102725_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-019-1039-z","article-title":"Effects of immunomodulation in classic infantile Pompe patients with high antibody titers","volume":"14","author":"Poelman","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.coi.2026.102725_bib27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clim.2019.01.009","article-title":"HLA- and genotype-based risk assessment model to identify infantile onset Pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA)","volume":"200","author":"De Groot","year":"2019","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coi.2026.102725_bib28","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.3233\/JND-159053","article-title":"Survival and developmental milestones among Pompe Registry Patients with classic infantile-onset pompe disease with different timing of initiation of treatment with enzyme replacement therapy","volume":"2","author":"Chien","year":"2015","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.coi.2026.102725_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067052","article-title":"Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT","volume":"8","author":"Banugaria","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2026.102725_bib30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijcard.2018.07.091","article-title":"Cardiac outcome in classic infantile Pompe disease after 13\u00a0years of treatment with recombinant human acid alpha-glucosidase","volume":"269","author":"van Capelle","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.coi.2026.102725_bib31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/humu.24148","article-title":"Update of the Pompe variant database for the prediction of clinical phenotypes: novel disease-associated variants, common sequence variants, and results from newborn screening","volume":"42","author":"de Faria","year":"2021","journal-title":"Hum Mutat"},{"key":"10.1016\/j.coi.2026.102725_bib32","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/humu.23854","article-title":"Extension of the Pompe mutation database by linking disease-associated variants to clinical severity","volume":"40","author":"Nino","year":"2019","journal-title":"Hum Mutat"},{"key":"10.1016\/j.coi.2026.102725_bib33","article-title":"Enzyme replacement therapy (ERT) on heart function changes the outcome in patients with infantile-onset pompe disease: a familial history","volume":"2023","author":"Lecis","year":"2023","journal-title":"Case Rep Pediatr"},{"key":"10.1016\/j.coi.2026.102725_bib34","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s13023-023-02919-8","article-title":"Safety outcomes and patients' preferences for home-based intravenous enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond","volume":"18","author":"Toscano","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.coi.2026.102725_bib35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jpeds.2014.10.068","article-title":"Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth","volume":"166","author":"Chien","year":"2015","journal-title":"J Pediatr"},{"key":"10.1016\/j.coi.2026.102725_bib36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijcard.2023.03.010","article-title":"Effects of enzyme replacement therapy on cardiac function in classic infantile Pompe disease","volume":"380","author":"Scheffers","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.coi.2026.102725_bib37","doi-asserted-by":"crossref","DOI":"10.1007\/BF02265613","article-title":"The conduction system in Pompe's disease","author":"Bharati","year":"1982","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.coi.2026.102725_bib38","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.0000075270.13497.2B","article-title":"Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy","author":"Arad","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.coi.2026.102725_bib39","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41436-020-01080-y","article-title":"Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction","volume":"23","author":"Li","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.coi.2026.102725_bib40","article-title":"Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: evidence from real-world experiences","volume":"23","author":"Chien","year":"2020","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.coi.2026.102725_bib41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13052-022-01219-4","article-title":"Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel","volume":"48","author":"Gragnaniello","year":"2022","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.coi.2026.102725_bib42","first-page":"18","article-title":"A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease","volume":"13","author":"Lim","year":"2017","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.coi.2026.102725_bib43","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fnagi.2014.00177","article-title":"Pompe disease: from pathophysiology to therapy and back again","volume":"6","author":"Lim","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.coi.2026.102725_bib44","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/15548627.2015.1009779","article-title":"Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease","volume":"11","author":"Lim","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.coi.2026.102725_bib45","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2018.04.025","article-title":"Therapeutic benefit of autophagy modulation in Pompe disease","volume":"26","author":"Lim","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2026.102725_bib46","doi-asserted-by":"crossref","first-page":"353","DOI":"10.15252\/emmm.201606547","article-title":"Modulation of mTOR signaling as a strategy for the treatment of Pompe disease","volume":"9","author":"Lim","year":"2017","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.coi.2026.102725_bib47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ymgme.2010.05.001","article-title":"Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease","volume":"100","author":"Ashe","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.coi.2026.102725_bib48","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jpeds.2013.03.002","article-title":"B-cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease","volume":"163","author":"Elder","year":"2013","journal-title":"J Pediatr"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:33:45Z","timestamp":1784540025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791526000026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":48,"alternative-id":["S0952791526000026"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2026.102725","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive study on the effect of alglucosidase alpha and immunomodulation on survival, motor and cardiac outcome, creatine kinase and antibody titers in classic infantile Pompe disease: the Monza experience","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2026.102725","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102725"}}